Medicinal cannabis sales in Germany are expected to top €1 billion (A$1.62b) by 2028 in the wake of regulatory changes in the European powerhouse.
Data and intelligence firm Prohibition Partners (PP) said the passing of the CanG bill legalising adult use and the associated MedCanG Act has resulted in significant growth in the medical market, with sales expected to reach €420 million (A$681m) this year.
It said the projected growth was fuelled by factors including the removal of cannabis from Germany’s schedule of narcotic drugs, which has eased previous bottlenecks associated with its handling, distribution, dispensing and prescription.
Continue reading...
